Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Hetrombopag Olamine Formulations
NCT05088655Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hetrombopag in aplastic anemia (3 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration vs Time Curve (0-120h) and 1 more. Started Jun 2021; status: completed.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05088655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088655.